Dr Melissa Johnson: Tiragolumab Plus Atezolizumab Improves Objective Response In Cityscape Trial

Dr Melissa Johnson: Tiragolumab Plus Atezolizumab Improves Objective Response in CITYSCAPE Trial

Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

CITYSCAPE: 1L tiragolumab + atezolizumab vs placebo + atezolizumab in PD-L1-selected NSCLC

CITYSCAPE: tiragolumab in NSCLC

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

Tiragolumab and atezolizumab in metastatic esophageal cancer

Dr. Melissa Johnson on Fox & Friends Discussing Immunotherapy in Lung Cancer - Sarah Cannon

Sarah Cannon Research Institute

NSCLC highlights at ASCO 2020

BEAT-meso: Phase III trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesothelioma

Melissa Johnson, MD, considers the recent data investigating atezolizumab in SCLC

BEAT-SC: Phase III trial of bevacizumab or placebo with atezolizumab & chemo in extensive-stage SCLC

Key learnings from the clinical science symposia

Dr Melissa Johnson: Treatment Advances Highlight the Immune System's Importance in Lung Cancer

December 2024 Research Roundtable: GLP-1 Agonists and Obesity, Lymphedema, and Lipedema

Lympha Press USA

Unexpected safety data in TREASURE: thoracic radiotherapy with atezolizumab in SCLC

ALICE: atezolizumab + immunogenic chemotherapy in metastatic TNBC

SOLTI-1503 PROMETEO: T-VEC + atezolizumab in patients with residual BC after neoadjuvant chemo

What Are Antibody Drug Conjugates? - OncTalk Lung 2023

GRACE - Global Resource for Advancing Cancer Education

Melissa Lumish, MD - Hematology and Oncology

University Hospitals